Anticoagulation in Patients With Venous Thromboembolism and Cancer

Pfizer1 enrolled

Overview

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neoplasms Embolism

Interventions

ApixabanDRUG

Anticoagulant

RivaroxabanDRUG

Anticoagulant

EdoxabanDRUG

Edoxaban

DabigatranDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A VTE diagnosis * Active cancer or history of cancer * Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH * Age ≥ 18 years at the date of index VTE (Venous thromboembolic) Exclusion Criteria: * Prior VTE diagnosis * Diagnosis of prior atrial fibrillation * Inferior Vena Cava (IVC) filter * Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed. * Pregnancy * More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date. * Patients with less than one day of follow up

Locations (1)

Pfizer Investigational Site

London, United Kingdom

Outcomes

Primary Outcomes

Recurrence of Thromboembolism

The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.

Time frame: 6 Months after treatment began as early as 1/1/2013

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.